Skin Cancer pp 363-377 | Cite as

Immunotherapy

  • Krzysztof Dabski
  • Frederick Helm

Abstract

Immunotherapy of neoplasms follows basic principles of immunization against infectious agents and is aimed at active or passive enhancement of the host’s own humoral and cellular immunity. Regardless of the modality used, the ultimate success is highly dependent on the degree of immune competence of the patient, as patients with the acquired immunodeficiency syndrome (AIDS) clearly attest (1).

Keywords

Tuberculosis Bacillus Pyrene Osteogenic Sarcoma Staphylococcus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fauci AS, Rosenberg SA, Sherwin SA, et al: Immunomodulators in clinical medicine. Ann Intern Med 1987; 106:421–433.PubMedGoogle Scholar
  2. 2.
    Berkelhammer J: In vitro testing in human immunotherapy. Semin Oncol 1974; 1:397–408.PubMedGoogle Scholar
  3. 3.
    Gutterman JU, Rosen RD, McCredie KB, et al: Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med 1973; 288:169–173.PubMedCrossRefGoogle Scholar
  4. 4.
    Mavligit GM, Gutterman JU, Hersh EM: Separation of viable from non-viable tumor cells using Ficoll-Hypaque density solution. Immunol Commun 1973; 2:463–472.PubMedGoogle Scholar
  5. 5.
    Gutterman JU, Hersh, Mavligit GM, et al: Cellmediated and humoral immune responses to acute leukemia cells and soluble leukemia antigen-relationship to immunocompetence and prognosis. Natl Cancer Inst Monogr 1973; 37:153–165.PubMedGoogle Scholar
  6. 6.
    Klein E, Papermaster BW, Case RW, et al: Immunological aspects of neoplasia, in Immunological Aspects of Neoplasia (Papers presented at the 26th Annual Symposium of Fundamental Cancer Research, Houston, 1973). Baltimore, Williams & Wilkins, 1975, pp 549–578.Google Scholar
  7. 7.
    Old LJ, Benacerraf B, Clarke DA, et al: The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res 1961; 21:1281–1300.PubMedGoogle Scholar
  8. 8.
    Unanue ER, Askonas BA, Allison AC: A role of macrophages in the stimulation of immune responses by adjuvants. J Immunol 1969; 103: 71–78.PubMedGoogle Scholar
  9. 9.
    Levis WR, Kraemer KH, Klinger WG, et al: Topical immunotherapy of basal cell carcinomas with dinitrochlorobenzene. Cancer Res 1973; 33:3036–3042.PubMedGoogle Scholar
  10. 10.
    Klein E: Tumors of the skin: X. Immunotherapy of cutaneous and mucosal neoplasms. NY State J Med 1968; 68:900–911.Google Scholar
  11. 11.
    Klein E, Holtermann OA: Immunotherapeutic approaches to the management of neoplasms. Natl Cancer Inst Monogr 1972; 35:379–402.PubMedGoogle Scholar
  12. 12.
    Klein E, Holtermann OA, Helm F, et al: Immunologic approaches to the management of primary and secondary tumors involving the skin and soft tissues: Review of a ten-year program. Transplant Proc 1975; VII:297–315.Google Scholar
  13. 13.
    Holtermann OA, Klein E, Casale GP: Selective cytotoxicity of peritoneal leukocytes for neoplastic cells. Cell Immunol 1973; 8:408–412.CrossRefGoogle Scholar
  14. 14.
    Holtermann OA, Papermaster B, Rosner D, Milgrom H, Klein E: Regression of cutaneous neoplasms following delayed-type hypersensitivity reactions to microbial antigens or lymphokines. J Med 1975; 6:157–168.PubMedGoogle Scholar
  15. 15.
    Eilber FR, Morton DL: Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 1970; 25:362–367.PubMedCrossRefGoogle Scholar
  16. 16.
    Klein E, Holtermann OA, Papermaster BP, et al: Immunologic approaches to various types of cancer using BCG and PPD. Conference on the use of BCG in therapy of cancer, Bethesda, MD. The National Institutes of Health. Natl Cancer Inst Monogr 1973; 39:229–240.PubMedGoogle Scholar
  17. 17.
    Falk RE, Mann P, Langer B: Cell-mediated immunity in human tumors: Abrogation by serum factors and non-specific effects of oral BCG therapy. Arch Surg 1973; 107:261–265.PubMedGoogle Scholar
  18. 18.
    Mathe G, Halle-Pannenko O, Bourut C: BCG in cancer immunotherapy: Results obtained with various BCG preparations in a screening study for systemic and adjuvants applicable to cancer immunoprophylaxis or immunotherapy. Natl Cancer Inst Monogr 1973; 39:107–113.PubMedGoogle Scholar
  19. 19.
    McNealy M, Civerchia L, Codish S, et al: Regional immunotherapy for lung cancer using intrapleural BCG, in Crispen R (Ed): Neoplasm Immunity: Theory and Application. Urbana, University of Illinois Press, 1974.Google Scholar
  20. 20.
    Falk RE, Landi S, Cohen Z, et al: Use of oral and intraperitoneal BCG in therapy of malignant melanoma and adenocarcinoma, in Crispen R (Ed): Neoplasm Immunity: Theory and Application. Urbana, University of Illinois Press, 1974.Google Scholar
  21. 21.
    Mathe G, Amiel JL, Schwarzenbeig L, et al: Active immunotherapy for acute lymphoid leukemia. Lancet 1969; 1:697–699.PubMedCrossRefGoogle Scholar
  22. 22.
    Sokal JE, Aungst CW, Grace JT: Immunotherapy in well controlled chronic myelocytic leukemia. NY State J Med 1973; 73:1180–1185.Google Scholar
  23. 23.
    Morton DL, Eilber FR, Malmgren RA, et al: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68:158–164.PubMedGoogle Scholar
  24. 24.
    Bröcker EB, Suter L, Czarnetzki BM, Macher E: BCG immunotherapy in stage I melanoma patients. Cancer Immunol Immunother 1986; 23:155–157.PubMedCrossRefGoogle Scholar
  25. 25.
    Normann SJ, Cornelius J: Cytokinetics of macrophage-mediated cytotoxicity. Cancer Res 1984; 44:2313–2320.PubMedGoogle Scholar
  26. 26.
    Herberman RB: Overview of role of macrophages, natural killer cells and antibody dependent cellular cytotoxicity as mediators of biological response modification. In: Chirigas MA, Mastrangelo MJ, Mitchell M, Krim M (Ed): Mediation of Cellular Immunity in Cancer by Immune Modifiers; Progress in Cancer Research and Therapy. Vol 19. New York, Raven Press, 1981.Google Scholar
  27. 27.
    Piessens WH, Heimann R, Legros N, et al: Effect of Bacillus Calmette-Guerin on mammary tumor formation and cellular immunity in dimethylbenz (a)anthracene-treated rats. Cancer Res 1971; 31:1061–1065.PubMedGoogle Scholar
  28. 28.
    Whitlock JP Jr, Cooper HL, Gelboin HV: Aryl hydrocarbon (benzopyrene) hydroxylase is stimulated in human lymphocytes by mitogens and benz(a)anthracene. Science 1972; 177:618–619.PubMedCrossRefGoogle Scholar
  29. 29.
    Bast RC Jr, Shears BW, Rapp HJ, et al: Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in guinea pig peritoneal macrophages: Benz(a)anthracene-induced increase of enzyme activity in vivo and in cell culture. J Natl Cancer Inst 1973; 51:675–678.PubMedGoogle Scholar
  30. 30.
    Hanna MG Jr, Snodgrass MJ, Zbar B, et al: Histopathology of tumor regression after intralesional injection of Mycobacterium bovis IV: Development of immunity to tumor cells and BCG. J Natl Cancer Inst 1973; 51:1897–1908.PubMedGoogle Scholar
  31. 31.
    Helm F, Helm J: Introduction to tumor immunotherapy. Int J Dermatol 1979; 18:205–210.PubMedGoogle Scholar
  32. 32.
    Sparks FC: Hazards and complications of BCG immunotherapy. Med Clin North Am 1976; 60:499–509.PubMedGoogle Scholar
  33. 33.
    Hersh EM, Gutterman JU, Mavligit GM, et al: BCG vaccine and its derivatives: Potential, practical considerations and precautions in human cancer immunotherapy. JAMA 1976; 235:646–650.Google Scholar
  34. 34.
    Levy NL, Mahaley MS, Day ED: Serum-mediated blocking of cell-mediated antitumor immunity in a melanoma patient: Association with BCG immunotherapy and clinical deterioration. Int J Cancer 1972; 10:244–248.PubMedCrossRefGoogle Scholar
  35. 35.
    Rosenberg SA, Rapp HJ: Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 1976; 60:419–430.PubMedGoogle Scholar
  36. 36.
    Halpern B (Ed): Corynebacterium parvum: Applications in Experimental and Clinical Oncology. New York, Plenum Press, 1975, p 444.Google Scholar
  37. 37.
    Halpern B, Crepin Y, Rabourdin A: An analysis of the increase in host resistance to isogenic tumor invasion in mice by treatment with Corynebacterium parvum, in Halpern B (Ed): Corynebacterium parvum: Applications in Experimental and Clinical Oncology. New York, Plenum Press, 1975, pp 191–199.Google Scholar
  38. 38.
    Halpern BN, Prevot AR, Biozzi G, et al: Stimulation de l’activite phagocytaire du systeme reticuloendothelial provoquee par Corynebacterium parvum. J Reticuloendothel Soc 1964; 1:77–96.Google Scholar
  39. 39.
    Olivotto M, Bomford R: In vitro inhibition of tumor cell growth and DNA synthesis by peritoneal and lung macrophages from mice injected with Corynebacterium parvum. Int J Cancer 1974; 13:478–488.PubMedCrossRefGoogle Scholar
  40. 40.
    Wilkinson PC, O’Neil GJ, McInroy RJ, et al: Chemotaxis of macrophages: The role of macrophage specific cytotoxin from anaerobic coryne-bacteria and its relation to immunopotentiation in vivo, in Wolstenholme GE, Knight J (Eds): Immunopotentiation. Ciba Found Symp 1973; 18:121–135.Google Scholar
  41. 41.
    Fauve RM, Hevin MB: Puovoire bactericide des macrophages spleniques et hepatiques de souris envers Listeria monocytogenes. Ann Inst Pasteur (Paris) 1971; 120:399–411.Google Scholar
  42. 42.
    Del Guercio P: Effect of adjuvants on the antibody response to a hapten on a thymus independent carrier. New Biol 1972; 238:213–214.Google Scholar
  43. 43.
    Howard JG, Christie GH, Scott MT: Biological effects of Corynebacterium parvum: IV. Adjuvant and inhibitory activities on B lymphocytes. Cell Immunol 1973; 7:290–301.CrossRefGoogle Scholar
  44. 44.
    Howard JG, Scott MT, Christie GH: Cellular mechanisms underlying the adjuvant activity of Corynebacterium parvum: Interactions of activated macrophages with T and B lymphocytes, in Wolstenholme GE, Knight J (Eds): Immunopotentiation. Ciba Found Symp 1973; 18:101–116.Google Scholar
  45. 45.
    Allwood GG, Asherson GL: Depression of delayed hypersensitivity by pretreatment with Freund-type adjuvants: II. Mechanism of the phenomenon. Clin Exp Immunol 1971; 9:259–266.PubMedGoogle Scholar
  46. 46.
    Allwood GG, Asherson GL: Depression of delayed hypersensitivity by pretreatment with Freund-type adjuvants: III. Depressed arrival of lymphoid cells at recently immunized lymph nodes in mice pretreated with adjuvants. Clin Exp Immunol 1972; 11:579–584.PubMedGoogle Scholar
  47. 47.
    Scott MT: Depression of delayed-type hypersensitivity by Corynebacterium parvum: Mandatory role of the spleen. Cell Immunol 1974; 13:251–263.PubMedCrossRefGoogle Scholar
  48. 48.
    Scott MT: Biological effects of the adjuvant Corynebacterium parvum: I. Inhibition of PHA, mixed lymphocyte and GVH reactivity. Cell Immunol 1972; 5:459–468.PubMedCrossRefGoogle Scholar
  49. 49.
    Scott MT: Biological effects of the adjuvant Corynebacterium parvum: II. Evidence for macrophage-T-cell interaction. Cell Immunol 1972; 5:469–479.PubMedCrossRefGoogle Scholar
  50. 50.
    Likhite VV, Halpern BN: Lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed Corynebacterium parvum. Cancer Res 1974; 34:341–344.PubMedGoogle Scholar
  51. 51.
    Woodruff MF, Dunbar N: The effect of Corynebacterium parvum and other reticuloendothelial stimulants on transplanted tumors in mice, in Wolstenholme GE, Knight J (Eds): Immunopotentiation. Ciba Found Symp 1973; 18:287–300.Google Scholar
  52. 52.
    Woodruff MF, Warner NL: Effect of Corynebacterium parvum on tumor growth in normal and athymic (nude) mice. J Natl Cancer Inst 1977; 58:111–116.PubMedGoogle Scholar
  53. 53.
    Israel L, Halpern B: Le Corynebacterium parvum dans les cancers avances. Premiere evaluation de l’activite therapeutique de cette immuno-stimuline. Nouv Presse Med 1972; 1:19–23.PubMedGoogle Scholar
  54. 54.
    Israel L, Edelstein RL: Non-specific immunostimulation with Corynebacterium parvum in human cancer, in Immunological Aspects of Neoplasia (MD Anderson Hospital and Tumor Institute at Houston). Baltimore, Williams & Wilkins, 1974, pp 485–504.Google Scholar
  55. 55.
    Oettgen HF, Pinsky CM, Delmonte L: Treatment of cancer with immunomodulators Corynebacterium parvum and Levamisole. Med Clin North Am 1976; 60:511–537.PubMedGoogle Scholar
  56. 56.
    Harris R, Zuhrie SR, Freeman CB, et al: Active immunotherapy in acute myelogenous leukemia and the induction of second and subsequent remissions. Br J Cancer 1978; 37:282–288.PubMedCrossRefGoogle Scholar
  57. 57.
    Summerfield GP, Gibbs TJ, Belingham AJ: Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukemia. Br J Cancer 1978; 40:736–742.CrossRefGoogle Scholar
  58. 58.
    Dugan M, Oratz R, Speyer J, et al: Relationship between immune responses to melanoma vaccine immunization and tumor progression in man. Clin Res 1987; 35:523A.Google Scholar
  59. 59.
    Whittaker JA, Bailey-Wood R, Hutchins S: Active immunotherapy for the treatment of acute myelogenous leukemia: Report of two controlled trials. Br J Hematol 1980; 45:389–400.CrossRefGoogle Scholar
  60. 60.
    Galton DAG, Peto R: Immunotherapy of acute myeloid leukemia. Br J Cancer 1978; 37:1–14.CrossRefGoogle Scholar
  61. 61.
    Vogler WR, Bartolucci AA, Omura GA, et al: A randomized clinical trial of remission induction, consolidation and chemo-immunotherapy maintenance in adult acute myeloblastic leukemia. Cancer Immunol Immunother 1978; 3:163–170.CrossRefGoogle Scholar
  62. 62.
    Baker MA, Taub RN, Carter WH, et al: Immunotherapy for remission maintenance in acute myeloblastic leukemia. Cancer Immunol Immunother 1982; 13:85–88.PubMedCrossRefGoogle Scholar
  63. 63.
    Currie GA: Masking of antigens on the Landschutz ascites tumor. Lancet 1967; 11:1336–1338.CrossRefGoogle Scholar
  64. 64.
    Lindenmann J, Klein PA: Immunological aspects of viral oncolysis. Recent Results Cancer Res 1967; 9:1–84.Google Scholar
  65. 65.
    Sanford BH: An alteration in tumor host compatibility induced by neuraminidase. Transplantation 1967; 5:1273–1279.PubMedCrossRefGoogle Scholar
  66. 66.
    Weiss L: Neuraminidase, sialic acids and cell interactions. J Natl Cancer Inst 1973; 50:3–19.PubMedGoogle Scholar
  67. 67.
    Ohta N, Pardee AB, McAuslan BR: Sialic acid contents and controls of normal and malignant cells. Biochim Biophys Acta 1968; 158:98–102.PubMedGoogle Scholar
  68. 68.
    Smith DF, Walborg EF: Isolation and chemical characterization of cell surface sialoglycopeptide fractions during progression of rat ascites hepatoma AS-30D. Cancer Res 1972; 32:543–549.PubMedGoogle Scholar
  69. 69.
    Boone CW, Paranjpe M, Orme T, et al: Virus augmented tumor transplantation antigens: Evidence for a helper antigen mechanism. Int J Cancer 1974; 13:543–551.PubMedCrossRefGoogle Scholar
  70. 70.
    Lindenmann J, Klein PA: Viral oncolysis: Increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 1967; 126:93–108.PubMedCrossRefGoogle Scholar
  71. 71.
    Hersey P, Edwards A, DAlessandro G, et al: Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. Cancer Immunol Immunother 1986; 22:221–231.PubMedGoogle Scholar
  72. 72.
    Fields BN, Hawkins K: Human infection with the virus of vesicular stomatitis during an epizootic. N Engl J Med 1967; 277:989–994.PubMedCrossRefGoogle Scholar
  73. 73.
    Cassel WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 1965; 18:863–868.PubMedCrossRefGoogle Scholar
  74. 74.
    Cassel WA, Weidenheim KM, Campbell WG Jr, Murray DR: Malignant melanoma: Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysate. Cancer 1986; 57:1302–1312.PubMedCrossRefGoogle Scholar
  75. 75.
    Murray DR, Cassel WA, Torbin AH, et al: Viral oncolysate in the management of malignant melanoma: II. Clinical studies. Cancer 1977; 40: 680–686.PubMedCrossRefGoogle Scholar
  76. 76.
    Boone CW, Austin FC, Gail M, et al: Melanoma skin test antigens prepared from vesicular stomatitis-infected tumor cells. Cancer 1978; 41:1781–1787.PubMedCrossRefGoogle Scholar
  77. 77.
    Alexander P, Delorme EJ, Hamilton LD, et al: Stimulation of anti-tumor activity of the host with RNA from immune lymphocytes, in Plescia OJ, Braun W (Eds): Nucleic Acid Immunology. New York, Springer-Verlag, 1968, p 527.Google Scholar
  78. 78.
    Santos GW: Application of marrow grafts in human disease: Its problems and potential. Contemp Top Immunobiol 1972; 1:143.Google Scholar
  79. 79.
    Alexander P, Delorme EJ, Hamilton LD, et al: Effect of nucleic acids from immune lymphocytes on rat sarcomata. Nature 1967; 213:569–572.PubMedCrossRefGoogle Scholar
  80. 80.
    Pilch YH, Fritze D, Kern D: Immune RNA in the immunotherapy of cancer. Med Clin North Am 1976; 60:567–583.PubMedGoogle Scholar
  81. 81.
    Pilch YA, Fritze D, Kern D: Immune cytolysis of human melanoma cells mediated by immune RNA. Behring Inst Mitt 1975; 56:186–196.Google Scholar
  82. 82.
    Lawrence HS: Transfer factor: Initiation and augmentation of cell-mediated immunity, in McCluskey RT, Cohen S (Eds): Mechanisms of Cell-Mediated Immunity. New York, John Wiley & Sons, 1974, p 289.Google Scholar
  83. 83.
    Neidhart JA, LoBuglio AF: Transfer factor therapy of malignancy. Semin Oncol 1974; 1:379–385.PubMedGoogle Scholar
  84. 84.
    Lawrence HS, Pappenheimer AM: Transfer of delayed hypersensitivity to diphtheria toxin in man. J Exp Med 1956; 104:321–355.PubMedCrossRefGoogle Scholar
  85. 85.
    LoBuglio AF, Neidhart JA, Hilberg RW: The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma. Cell Immunol 1973; 7:159–165.PubMedCrossRefGoogle Scholar
  86. 86.
    Bukowski RM, Deodhar S, Hewlett JS, et al: Randomized controlled trial of transfer factor in stage II malignant melanoma. Cancer 1983; 51:269–272.PubMedCrossRefGoogle Scholar
  87. 87.
    Epstein DA, Torrence PF, Friedman RM: Doublestranded RNA inhibits a phosphoprotein phosphatase present in interferon-treated cells. Proc Natl Acad Sci USA 1980; 77:107–111.PubMedCrossRefGoogle Scholar
  88. 88.
    Ball LA, White CN: Nuclease activation by double-stranded RNA and by 2,5-oligoadenylate in extracts of interferon-treated chick cells. Virology 1979; 93:348–356.PubMedCrossRefGoogle Scholar
  89. 89.
    Wheelock EF: Interferon-like virus inhibitor induced in human leukocytes by phytohemagglutinin. Science 1965; 149:310–311.CrossRefGoogle Scholar
  90. 90.
    Heron I, Hokland M, Berg K: Enhanced expression of beta-2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 1978; 75:6215–6219.PubMedCrossRefGoogle Scholar
  91. 91.
    Fridman WH, Gresser I, Bandu MT, et al: Interferon enhances the expression of Fc γ receptors. J Immunol 1980; 124:2436–2441.PubMedGoogle Scholar
  92. 92.
    Herberman RR, Ortaldo JR, Bonnard GD: Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 1979; 277:221–223.PubMedCrossRefGoogle Scholar
  93. 93.
    Heron I, Hokland M, Moller-Larsen A, et al: The effect of interferon on lymphocyte-mediated effector cell functions: Selective enhancement of natural killer cells. Cell Immunol 1979; 42:183–187.PubMedCrossRefGoogle Scholar
  94. 94.
    Huang KY, Donahoe RM, Gordon F, et al: Enhancement of phagocytosis by interferoncontaining preparations. Infect Immun 1971; 4:581–588.PubMedGoogle Scholar
  95. 95.
    Zarling JM, Sosman S, Eskra L, et al: Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J Immunol 1978; 121:2002–2004.PubMedGoogle Scholar
  96. 96.
    Lindahl P, Leary P, Gresser I: Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972; 69:721–725.PubMedCrossRefGoogle Scholar
  97. 97.
    Schultz RM, Papamatheakis JD, Chirigos MA: Interferon: An inducer of macrophage activation by polyanions. Science 1977; 197:674–676.PubMedCrossRefGoogle Scholar
  98. 98.
    Trinchieri G, Santoli D: Antiviral activity induced by culturing lymphocytes with tumor-derived or virus transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978; 147:1314–1333.PubMedCrossRefGoogle Scholar
  99. 99.
    Senik A, Gresser I, Maury C, et al: Enhancement by interferon of natural killer activity in mice. Cell Immunol 1979; 44:186–200.PubMedCrossRefGoogle Scholar
  100. 100.
    Djeu JY, Heinbaugh JA, Holden H, et al: Augmentation of mouse natural killer activity by interferon and interferon inducers. J Immunol 1979; 122: 175–181.PubMedGoogle Scholar
  101. 101.
    Stewart WE, Blalock JE, Burke DC, et al: Interferon nomenclature (Letter). J Immunol 1980; 125:2353.Google Scholar
  102. 102.
    Kirchner H, Zavatsky R, Engler H, et al: Production of interferon in the murine mixed lymphocyte culture: II. Interferon production is a T-cell-dependent function, independent of proliferation. Eur J Immunol 1979; 9:824–826.PubMedCrossRefGoogle Scholar
  103. 103.
    Salvin SB, Younger JS, Nishio J: Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity. J Natl Cancer Inst 1975; 55:1233–1236.PubMedGoogle Scholar
  104. 104.
    Crane JL Jr, Glasgow LA, Kern ER, et al: Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst 1978; 61:871–874.PubMedGoogle Scholar
  105. 105.
    Cantell K, Hirvonen S: Large scale production of human leukocyte interferon containing 108 units per ml. J Gen Virol 1978; 39:541–543.PubMedCrossRefGoogle Scholar
  106. 106.
    Nagata S, Taira H, Hall A, et al: Synthesis in E. coli of a polipeptide with human leukocyte interferon activity. Nature 1980; 284:316–320.PubMedCrossRefGoogle Scholar
  107. 107.
    Edwards L, Levine N, Weidner M, et al: Effect of intralesional α2-interferon on actinic keratoses. Arch Dermatol 1986; 122:779–782.PubMedCrossRefGoogle Scholar
  108. 108.
    Billiau A: Perspectives in cancer research: The clinical value of interferons as antitumor agents. Eur J Cancer Clin Oncol 1981; 17:949–967.PubMedCrossRefGoogle Scholar
  109. 109.
    Stiehm ER, Kronenberg LH, Rosenblatt HM, et al: Interferon: Immunobiology and clinical significance. UCLA conference. Ann Intern Med 1982; 96:80–93.PubMedGoogle Scholar
  110. 110.
    Brostrom LA: On the natural history of osteosarsoma. Thesis, Karolinska Institute, Stockholm. Acta Orthop Scand 1979; Suppl 183.Google Scholar
  111. 111.
    Schonfeld A, Schattner A, Crespi M, et al: Intramuscular human interferon-β injections in treatment of condyloma acuminata. Lancet 1984; 2:1002–1005.Google Scholar
  112. 112.
    Horoszewicz JS, Leong SS, Ito M, et al: Human fibroblast interferon in human neoplasia: Clinical and laboratory study. Cancer Treat Rep 1978; 62:1899–1906.PubMedGoogle Scholar
  113. 113.
    Horoszewicz JS, Leong SS, Dolen JG, et al: Purified human fibroblast interferon and neoplasia: Pharmacokinetic studies and selective antiproliferative properties in vivo, in Khan A, Hill NO, Dorn GL (Eds): Interferon: Properties and Clinical Uses. Dallas, Leland Fikes Foundation Press of the Wedley Institutes, 1980, pp 661–666.Google Scholar
  114. 114.
    Ishihara K, Hayasaka K, Hasegawa F: Treatment of malignant melanoma by intratumoral administration of human fibroblast interferon, in Kono R, Vilcek J (Eds): The Clinical Potential of Interferons: Treatment of Viral Diseases and Malignant Tumors. (Proceedings of the International Conference on Clinical Potentials of Interferons in Viral Diseases and Malignant Tumors, Dec. 2–4, 1980). University of Tokyo Press, 1982, Japan Medical Research Foundation Publication No. 15, pp 245–256.Google Scholar
  115. 115.
    Retsas S, Priestman TJ, Newton KA, et al: Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer 1983; 51:273–276.PubMedCrossRefGoogle Scholar
  116. 116.
    Padovan I, Brodarec I, Knezevic M, et al: Effect of interferon in therapy of skin and head and neck tumors. Cancer Res Clin Oncol 1981; 100:295–310.CrossRefGoogle Scholar
  117. 117.
    Ikic D, Krusic J, Cupak D, et al: The use of human leukocytic interferon in patients with cervical cancer and basocellular cancer of the skin. Proceedings of the Symposium on Clinical Use of Interferon. Zagreb, Yugoslav Academy of Science & Arts, 1975, pp 239–242.Google Scholar
  118. 118.
    Goldstein AL, Cohen GH, Rossio JL, et al: Use of thymosin in the treatment of primary immunodeficiency diseases and cancer. Med Clin North Am 1976; 60:591–606.PubMedGoogle Scholar
  119. 119.
    Bach J, Dardenne M, Goldstein AL: Appearance of T cell markers in bone marrow rosette forming cells after incubation with thymosin, a thymic hormone. Proc Natl Acad Sci USA 1971; 68:2734–2738.PubMedCrossRefGoogle Scholar
  120. 120.
    Scheid MP, Hoffman MR, Komuro K, et al: Differentiation of T lymphocytes induced by preparations from thymus and by non-thymic agents: The determined state of the precursor cell. J Exp Med 1973; 138:1027–1032.PubMedCrossRefGoogle Scholar
  121. 121.
    Goldstein AL, Thurman GB, Komuro K, et al: The role of the thymosin and the endocrine thymus in the ontogenesis and function of T cells, in Smith EE, Robbins DW (Eds): Molecular Approaches to Immunology. New York, Academic Press, 1975, pp 243–265.Google Scholar
  122. 122.
    Asanuma Y, Goldstein AL, White A: Reduction in the incidence of wasting disease in neonatally thymectomized CBA/W mice by the injection of thymosin. Endocrinology 1970; 86:600–610.PubMedCrossRefGoogle Scholar
  123. 123.
    Goldstein AL, Asanuma Y, Battisto JR, et al: Influence of thymosin on cell-mediated and humoral responses in normal and immunologically deficient mice. J Immunol 1970; 104:359–366.PubMedGoogle Scholar
  124. 124.
    Goldstein AL, Banerjee S, Schneebeli GL, et al: Acceleration of lymphoid tissue regeneration in X-irradiated CBA/W mice by injection of thymosin. Radiat es 1970; 41:579–593.CrossRefGoogle Scholar
  125. 125.
    Law L, Goldstein AL, White A: Influence of thymosine on immunological competence of lymphoid cells from thymectomized mice. Nature 1968; 219:1391–1392.PubMedCrossRefGoogle Scholar
  126. 126.
    Zisblatt M, Goldstein AL, Lilly F, et al: Acceleration by thymosin in the development of resistance to murine sarcoma virus-induced tumor in mice. Proc Natl Acad Sci USA 1970; 66:1170–1174.PubMedCrossRefGoogle Scholar
  127. 127.
    Lipson SD, Chretien PB, Makuch R, et al: Thymosin immunotherapy in patients with small cell carcinoma of the lung: Correlation of in vitro studies with clinical course. Cancer 1979; 43:863–870.PubMedCrossRefGoogle Scholar
  128. 128.
    Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD 2. Proc Natl Acad Sci USA 1986; 83:8694–8698.PubMedCrossRefGoogle Scholar
  129. 129.
    Rosen ST, Zimmer AM, Goldman-Leikin R, et al: Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labelled monoclonal antibody: An Illinois cancer council study. J Clin Oncol 1987; 5:562–573.PubMedGoogle Scholar
  130. 130.
    Chiba M, Jimbow K, Kizukuri K, et al: Chemoimmunotherapy for disseminated malignant melanoma with OTIC, ACNU, VCR and OK-432: Case presentation of two complete and one partial response out of fifteen attempts. J Dermatol 1982; 9:23–30.PubMedGoogle Scholar
  131. 131.
    Balch CM, Smalley RV, Bartolucci AA, et al: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): Prognostic factors analysis and preliminary results of immunotherapy. Cancer 1982; 49:1079–1084.PubMedCrossRefGoogle Scholar
  132. 132.
    Blume MR, Rosenbaum EH, Cohen RJ, et al: Adjuvant immunotherapy of high risk stage I melanoma with transfer factor. Cancer 1981; 47:882–888.PubMedCrossRefGoogle Scholar
  133. 133.
    Lipton A, Harvey HA, Lawrence B, et al: Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer 1983; 51:57–60.PubMedCrossRefGoogle Scholar
  134. 134.
    Terry WD, Rosenberg A (Eds): Immunotherapy of human cancer, in Excerpta Medica, New York, Elsevier Science Publishers, 1982 (Section VI: Melanoma).Google Scholar
  135. 135.
    Morton DL, Eilber PK, Malmgren RA, et al: Immunological factors which influence response to immunotherapy in melanoma. Surgery 1970; 68:158–164.PubMedGoogle Scholar
  136. 136.
    Nathanson L: Regression of intradermal malignant melanoma after intralesional injection of Mycebacterium bovis strain BCG. Cancer Chemother Rep 1972; 56:659–665.PubMedGoogle Scholar
  137. 137.
    Terry WD: Foreward to symposium on immunotherapy in malignant disease. Med Clin North Am 1976; 60:387–388.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1988

Authors and Affiliations

  • Krzysztof Dabski
  • Frederick Helm

There are no affiliations available

Personalised recommendations